TCMDMEDIUM SIGNALFINANCIAL10-K

TCMD delivered solid revenue growth of 12.5% to $329.5 million with meaningfully improved operating leverage, as operating income expanded substantially to $29.3 million.

The company demonstrated strong operational execution with revenue growth accelerating from 7% in the prior year to 12.5%, while operating margins expanded significantly due to improved cost management. The addition of technology implementation risks and regulatory compliance concerns in the risk factors suggests management is proactively addressing potential headwinds in their evolving business model.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

TCMD showed robust top-line growth with revenue increasing 12.5% to $329.5 million and gross profit expanding 15.4% to $250.1 million, indicating improving pricing power or product mix. Operating income grew substantially by 32% to $29.3 million, demonstrating strong operational leverage and cost discipline. The balance sheet strengthened with total liabilities declining 32.3% to $55.0 million and inventory optimization reducing stock levels by 24.9%, though cash decreased modestly to $83.4 million, likely reflecting business investments or capital allocation activities.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-32.3%
$81.3M$55.0M

Liabilities reduced 32.3% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+32%
$22.2M$29.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
-24.9%
$18.7M$14.0M

Inventory reduced 24.9% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
+15.4%
$216.7M$250.1M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+12.5%
$293.0M$329.5M

Revenue growing 12.5% — solid top-line momentum, watch margins for quality of growth.

Net Income
P&L
+12.5%
$17.0M$19.1M

Net income grew 12.5% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-11.6%
$94.4M$83.4M

Cash decreased 11.6% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
- Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results.
Further, requirements to comply with new laws, regulations and guidance may have an adverse effect on our financial condition and results of operations.
- Our products are currently made available to authorized users of the Department of Veterans Affairs Federal Supply Schedule and if we were no longer eligible to sell our products through such channel, our business may be adversely affected.
For our respiratory therapy product, we have a durable medical equipment ( DME ) distribution model, through which we sell the AffloVest product to accredited DME providers, whose representatives gather and submit documentation for payer reimbursement, train patients on use of the device, and provide ongoing patient support.
For the year ended December 31, 2025, we generated revenue of $329.5 million and had net income of $19.1 million.
+7 more — sign up free →
REMOVED
You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the SEC that advise of the risks and factors that may affect our business.
Government Regulation, Compliance and Legal Risks - We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could be required to repay amounts previously received, and could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results.
For our respiratory therapy products, we have a durable medical equipment ( DME ) distribution model, utilizing mature comprehensive respiratory DME provider representatives to service patients.
We sell the AffloVest product to accredited DME providers, whose representatives gather and submit documentation for payer reimbursement, train patients on use of the device, and provide ongoing patient support.
For the year ended December 31, 2024, we generated revenue of $293.0 million and had net income of $17.0 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →